Prosecution Insights
Last updated: November 12, 2026
Application No. 18/698,694

SUBSTITUTED PYRIMIDIN-4(3H)-ONES FOR USE IN TREATING CANCER

Non-Final OA §102
Filed
Apr 04, 2024
Priority
Oct 06, 2021 — provisional 63/252,970 +2 more
Examiner
LEESER, ERICH A
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Navire Pharma Inc.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
95%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
795 granted / 972 resolved
+21.8% vs TC avg
Moderate +13% lift
Without
With
+13.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
37 currently pending
Career history
991
Total Applications
across all art units

Office Action

§102
DETAILED ACTION This action is in response to Applicant’s submission dated February 26, 2025, in which Applicant amended claims 3, 6, 8-10, 13, 19, 25, 27, 35, 37-38, 41, and 54-56, and cancelled claims 2, 4-5, 7, 11-12, 14-18, 20-24, 26, 28-34, 36, 39-40, 42-45, and 48-53. Information Disclosure Statement The references contained in the IDS dated February 26, 2025 are made of record. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3, 25, 35, 41, 46, and 56 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Jones, et al., US 2020/0048249, which teaches the presently claimed compound for use in treating cancer in a subject harboring a PTPN11 mutation in an amount between 5 mg to 2 g per day through oral or intravenous administration. The references compounds exhibit the same activity as the compounds of the instant claims. Claim Objections Claims 6, 8-10, 13, 19, 27, 37-38, 47, and 54-55 are objected to as being dependent upon rejected independent claim 1, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICH A LEESER/Primary Examiner, Art Unit 1622 United States Patent and Trademark Office Tel. No.: (571) 272-9932
Read full office action

Prosecution Timeline

Apr 04, 2024
Application Filed
Jun 30, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790320
SULPHAMOYL UREA DERIVATIVES CONTAINING ALKYL-OXACYCLOALKYL MOIETY AND USES THEREOF
3y 8m to grant Granted Nov 10, 2026
Patent 12790351
COVALENT RAS INHIBITORS AND USES THEREOF
3y 0m to grant Granted Nov 10, 2026
Patent 12778954
METHODS OF TREATING GOUT
3y 8m to grant Granted Nov 03, 2026
Patent 12778945
TREATMENTS FOR CUSHING'S SYNDROME THAT DO NOT SIGNIFICANTLY AFFECT CARDIAC RHYTHMS
2y 11m to grant Granted Nov 03, 2026
Patent 12780802
METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS
1y 5m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
95%
With Interview (+13.4%)
Low
PTA Risk
Based on 972 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month